Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bart Staels

Showing results (101-110 of 638) with videos related to

Pageof 64
Sort By:
Current Opinion in Pharmacology|March 23, 2005
Role of the PPAR family of nuclear receptors in the regulation of metabolic and cardiovascular homeostasis: new approaches to therapyGiulia Chinetti-Gbaguidi, Jean-Charles Fruchart, Bart Staels
Circulation Journal : Official Journal of the Japanese Circulation Society|July 8, 2014
Macrophage phenotypes and their modulation in atherosclerosisFederica De Paoli, Bart Staels, Giulia Chinetti-Gbaguidi
Current Opinion in Lipidology|June 24, 2015
Bariatric surgery, lipoprotein metabolism and cardiovascular riskAnne Tailleux, Konstantinos Rouskas, François Pattou, et al.
Atherosclerosis|June 15, 2026
Hepatic amino acid metabolism in liver, cardiovascular, kidney and metabolic diseasesEmily Flam, Anne Tailleux, Joel Haas, et al.
Current Opinion in Lipidology|November 5, 2013
Pharmacological interventions in human HDL metabolismJan-Willem Balder, Bart Staels, Jan A Kuivenhoven
Metabolism: Clinical and Experimental|August 3, 2021
Intestine-liver crosstalk in Type 2 Diabetes and non-alcoholic fatty liver diseaseMargaux Nawrot, Simon Peschard, Sophie Lestavel, et al.
FEBS Letters|April 14, 2011
Control of nuclear receptor activities in metabolism by post-translational modificationsWahiba Berrabah, Pierrette Aumercier, Philippe Lefebvre, et al.
Fundamental & Clinical Pharmacology|November 16, 2007
Glitazones in the treatment of cardiovascular risk factorsMohamed Amine Bouhlel, Giulia Chinetti-Gbaguidi, Bart Staels
The Journal of Clinical Investigation|April 4, 2017
Distinct but complementary contributions of PPAR isotypes to energy homeostasisVanessa Dubois, Jérôme Eeckhoute, Philippe Lefebvre, et al.
Pharmacological Reviews|September 13, 2025
The evolution of lipid-lowering drugs in the management of cardiovascular disease risk: From the first cardiovascular disease risk-reducing therapies to the novel challenging strategiesDoriane Henry, Eric Baugé, Bart Staels, et al.
Pageof 64

Showing results (101-110 of 638) with videos related to

Sort By:
Pageof 64
Current Opinion in Pharmacology|March 23, 2005
Role of the PPAR family of nuclear receptors in the regulation of metabolic and cardiovascular homeostasis: new approaches to therapyGiulia Chinetti-Gbaguidi, Jean-Charles Fruchart, Bart Staels
Circulation Journal : Official Journal of the Japanese Circulation Society|July 8, 2014
Macrophage phenotypes and their modulation in atherosclerosisFederica De Paoli, Bart Staels, Giulia Chinetti-Gbaguidi
Current Opinion in Lipidology|June 24, 2015
Bariatric surgery, lipoprotein metabolism and cardiovascular riskAnne Tailleux, Konstantinos Rouskas, François Pattou, et al.
Atherosclerosis|June 15, 2026
Hepatic amino acid metabolism in liver, cardiovascular, kidney and metabolic diseasesEmily Flam, Anne Tailleux, Joel Haas, et al.
Current Opinion in Lipidology|November 5, 2013
Pharmacological interventions in human HDL metabolismJan-Willem Balder, Bart Staels, Jan A Kuivenhoven
Metabolism: Clinical and Experimental|August 3, 2021
Intestine-liver crosstalk in Type 2 Diabetes and non-alcoholic fatty liver diseaseMargaux Nawrot, Simon Peschard, Sophie Lestavel, et al.
FEBS Letters|April 14, 2011
Control of nuclear receptor activities in metabolism by post-translational modificationsWahiba Berrabah, Pierrette Aumercier, Philippe Lefebvre, et al.
Fundamental & Clinical Pharmacology|November 16, 2007
Glitazones in the treatment of cardiovascular risk factorsMohamed Amine Bouhlel, Giulia Chinetti-Gbaguidi, Bart Staels
The Journal of Clinical Investigation|April 4, 2017
Distinct but complementary contributions of PPAR isotypes to energy homeostasisVanessa Dubois, Jérôme Eeckhoute, Philippe Lefebvre, et al.
Pharmacological Reviews|September 13, 2025
The evolution of lipid-lowering drugs in the management of cardiovascular disease risk: From the first cardiovascular disease risk-reducing therapies to the novel challenging strategiesDoriane Henry, Eric Baugé, Bart Staels, et al.
Pageof 64